Sun Pharmaceutical Industries Limited has announced a board meeting scheduled for November 5, 2025, to consider and approve the unaudited standalone financial results for the quarter and half-year ended September 30, 2025 (Q2). The company also stated that the trading window, which was closed on October 1, 2025, will remain closed until November 7, 2025.
Board Meeting Announcement
A meeting of the Board of Directors at Sun Pharmaceutical Industries Limited has been scheduled to take place on Wednesday, November 5, 2025. The primary agenda of the meeting is to review and approve the unaudited standalone financial results.
Financial Results Focus
The board will specifically address the financial performance for the quarter and half-year which concluded on September 30, 2025. This encompasses the period spanning from July 1, 2025, to September 30, 2025 (Q2).
Trading Window Closure
The company has declared a trading window closure. Effective from October 1, 2025, the trading window has been closed and will remain so until November 7, 2025. This measure ensures compliance and prevents insider trading during the sensitive period leading up to the financial results announcement.
Source: BSE
